No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Korea United Pharm Inc. is a South Korean enterprise dedicated to the development, production, and distribution of a wide array of pharmaceutical products. The company's extensive portfolio encompasses therapeutic solutions for various medical fields, such as the respiratory, musculoskeletal, gastrointestinal, cardiovascular, and central nervous systems, in addition to treatments for cancer, infections, allergies, and immune disorders. It also supplies over-the-counter drugs. While deeply rooted in the South Korean market, the firm extends its reach internationally, exporting its medications to nearly 40 countries. Founded in 1987, Korea United Pharm Inc. is headquartered in Seoul, South Korea.
www.kup.co.krNo one on the platform currently holds 033270.KS.
No tracked institution reports a position in 033270.KS as of their last filing.
No one on the platform has traded 033270.KS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.8% | 10.2% | 11.1% | — | — | — |
| Rev. Growth % | 0.0% | 6.0% | ||||
| Profit Margin % | 13.3% | 14.4% | 13.8% | |||
| Free Cash Flow Margin % | 9.6% | 9.5% | 8.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $303.5B | +4.3% | $2966.00 | $2966.00–$2966.00 | — | 1 |
| 2027 | $320.3B | +5.5% | $2717.00 | $2717.00–$2717.00 | — | 1 |
| 2028 | $338.4B | +5.7% | $2783.00 | $2783.00–$2783.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $20150.00 |
| -1.95% |
| $224.4B |
| — |
| 009290.KSKwang Dong Pharmaceutical Co., Ltd. | $6370.00 | -0.16% | $316.3B | — |
| 058820.KQCMG Pharmaceutical Co., Ltd. | $564.00 | -3.09% | $83.4B | — |
Source: Financial Modeling Prep · peers by sector/industry